ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 222

OA Phenotypes Rather Than Disease Stage Drive Structural Progression – Identification of Structural Progressors from 2 Phase III Randomized Clinical studies with Symptomatic Knee OA

Morten Asser Karsdal1, Anne C. Bay-Jensen2, Asger Bihlet3, Peter Alexandersen4, Inger Byrjalsen3, Bente J. Riis3 and Claus Christiansen3, 1Nordic Bioscience, Biomarkers and Research, Herlev, Denmark, 2Cartilage Biomarkers and Research, Nordic Bioscience, Herlev, Denmark, 3Nordic Bioscience, Herlev, Denmark, 4Center for Clinical and Basic Research, Vejle, Denmark

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: Biomarkers, Osteoarthritis, pain and phenotypes, Personalized Medicine

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Osteoarthritis - Clinical Aspects: Imaging and Biomechanics

Session Type: Abstract Submissions (ACR)

Background/Purpose: Osteoarthritis (OA) is a heterogeneous disorder, with several possible drivers of disease progression. Up to 50% of OA patients do not structurally progress, emphasizing the importance for identification of fast progressors, and the phenotypes associated with that. There is therefore a medical need for in-depth, post-hoc analysis of clinical studies in OA. The aim of the analysis was to investigate the associations between JSW, KL-score, pain and JSN (joint space narrowing), as well as BMI, by combining data from two phase III studies (N=2,206) to identify key characteristics for disease progression.

Methods: This is a post-hoc analysis of two randomized, double-blind, multi-center, placebo-controlled trials NCT00486434 and NCT00704847 evaluating the efficacy and safety of 2-years treatment with oral salmon calcitonin in subjects with painful knee OA, enrolling 1,176 and 1,030 subjects. The analysis includes baseline data on KL-score, JSW, pain and function scores from the WOMAC questionnaire, as well as demographics.

Results: Diagnostic measures; At baseline, combined analysis of signal and non-signal knees, the mean JSW was comparable in knees of KL-0 and -1 and significantly decreased with increasing KL-2, -3 and -4 (p<0.01). JSW (KL2/3) was significantly lower in the non-target knees as compared to the target knees (3.32±0.03mm vs. 3.42±0.02mm, p<0.0001, mean±SEM). There was a clear positive and significant correlation between KL-score and WOMAC pain and total WOMAC, albeit the variance in pain measures was from min-to-max for all KL categories, emphasizing the heterogeneity of this patient population and pain perception. Prognostic measures; 32% of target knees did not progress, and only 51% had changes over minimum significant change (MSC). Only minor differences were observed between target and non-target and KL-2 versus KL-3. The mean JSN at 2-years for the non-target knee was 0.25±0.02mm and 0.32±0.02 for the target knee (p<0.01). Patients were stratified in quartiles for WOMAC pain and BMI, as well as WOMAC pain and KL-scores, and investigated for JSN. Q3 WOMAC pain progressed more than Q2 and Q4 in both scenarios.

Conclusion: These data from the largest clinical trial dataset in OA to date clearly describe significant associations between KL-score, JSW, pain and BMI in patients with symptomatic knee OA.  50% of patients did not progress more than MSC, highlighting the importance for identification of structural progressors and the phenotypes associated with these. Patients with symptomatic OA at baseline progressed significantly faster than patients with asymptomatic disease, however with important variations that need accounting for when designing clinical trials, such as relations to pain, BMI and JSN. Different levels of progression were observed in relation to KL score and pain, in which the third WOMAC pain quartile (Q3), but not the fourth quartile (Q4), progressed significantly faster than the first and second pain quartiles. These results suggest that disease phenotypes rather than disease status are responsible for disease progression. Consequently, this dataset is ideally suited for identification of different phenotypes of OA, and biomarkers associated with those.


Disclosure:

M. A. Karsdal,

Nordic Bioscience Diagnostic,

3;

A. C. Bay-Jensen,

Nordic Bioscience Diagnostic,

1;

A. Bihlet,

Nordic Bioscience Diagnostic,

1;

P. Alexandersen,

CCBR,

3;

I. Byrjalsen,

Nordic Bioscience Diagnostic,

3;

B. J. Riis,

Nordic Bioscience Diagnostic,

1;

C. Christiansen,

Nordic Bioscience Diagnostic,

1.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/oa-phenotypes-rather-than-disease-stage-drive-structural-progression-identification-of-structural-progressors-from-2-phase-iii-randomized-clinical-studies-with-symptomatic-knee-oa/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology